Search
for

    Glossaryp21

    protein that inhibits cell cycle progression for DNA repair

    p21 is a protein that acts as a regulator of the cell cycle. It is known for its role in inhibiting the activity of cyclin-dependent kinases (CDKs), which are crucial for cell division. By doing so, p21 can halt the cell cycle, allowing for DNA repair or triggering cell death if the damage is irreparable. This function is particularly important in preventing the proliferation of damaged cells, which can lead to cancer.

    Related Terms

    Sort by

    Community Join

    30 / 1000+ results

      community im 23, hair loss problem

       6 upvotes 11 years ago
      A 23-year-old experiencing hair loss tried olive oil, coconut oil, and hair growth shampoos without success. They are seeking advice on whether to start treatments like Minoxidil, finasteride, or RU58841.

      community New Hair Loss Cure: AMP-303 Is Back. It’s what PP405 should have been.

      in Research/Science  5 upvotes 2 months ago
      AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

      community M21 one year progress fin only

      in Progress Pictures  51 upvotes 1 year ago
      A 21-year-old shares their one-year progress using finasteride for hair loss, experiencing initial shedding but eventual regrowth, especially on the crown. They consider switching to dutasteride due to continued hair loss at the front temple and mid-scalp areas.

      community My summation of PP405 - looks promising

      in Research/Science  206 upvotes 1 year ago
      PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
      PP405 Identity Research

      community PP405 Identity Research

      in Research  292 upvotes 10 months ago
      PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

      community 20% discount code at Anageninc

      in Chat  2 upvotes 1 year ago
      A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

      community Pp405 phase 2a clinical results

      in Research/Science  40 upvotes 1 year ago
      PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

      community Pp405 full presentation on new topical

      in Product  105 upvotes 3 months ago
      A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

      community PP405 Phase 2a press release with early results

      in Research/Science  700 upvotes 1 year ago
      PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

      community PP405 - hair stem cell stimulation

      in Research/Science  53 upvotes 2 years ago
      PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

      community Why doesn't phase 3 of PP405 start straight away?

      in Chat  14 upvotes 6 months ago
      Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

      community Approve PP405 quickly you coward

      in Satire  193 upvotes 11 months ago
      Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

      community I wish pp405 work and i have full head of hair in 2028-2030

      in Chat  106 upvotes 8 months ago
      People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

      community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi

      in Treatment  13 upvotes 6 years ago
      PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

      community PP405 Update and My Take on Pelage

      in Research/Science  86 upvotes 8 months ago
      Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

      community Put P5P in my shampoo, reduced itch a lot!

      in Chat  4 upvotes 3 years ago
      The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

      community Age 21 to 25, N3 to N2 in 4 years

      in Progress Pictures 1 year ago
      A user shared their hair regrowth journey from age 21 to 25 using finasteride and a carnivore diet. Other users debated the effectiveness of diet changes versus genetic factors in hair loss.

      community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?

      in Treatment  30 upvotes 6 months ago
      A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

      community A Short Recap on PP405 and AAD 2026

      in Update 2 months ago
      PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.